BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36789669)

  • 1. PRAME immunohistochemistry can distinguish melanocytic pseudonests of lichenoid reactions from melanoma in situ.
    Roy SF; Panse G; McNiff JM
    J Cutan Pathol; 2023 May; 50(5):450-454. PubMed ID: 36789669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lichenoid dermatoses with pseudomelanocytic nests vs inflamed melanoma in situ: A comparative study.
    Panse G; McNiff JM
    J Cutan Pathol; 2021 Jun; 48(6):745-749. PubMed ID: 33350494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Melanocytic Nests Arising in Lichenoid Inflammation": Reappraisal of the Terminology "Melanocytic Pseudonests".
    Chung HJ; Simkin AD; Bhawan J; Wolpowitz D
    Am J Dermatopathol; 2015 Dec; 37(12):940-3. PubMed ID: 26588340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MART-1 is a reliable melanocytic marker in lichen planus-like keratosis: a study on 70 cases.
    Gavino AC; Woods MT; Andea AA
    Am J Dermatopathol; 2011 Oct; 33(7):675-80. PubMed ID: 21885940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melan-a-positive "pseudomelanocytic nests": a pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin.
    Beltraminelli H; Shabrawi-Caelen LE; Kerl H; Cerroni L
    Am J Dermatopathol; 2009 May; 31(3):305-8. PubMed ID: 19384076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanocytic and pseudomelanocytic nests coexist in interface dermatitis from head-neck sun-exposed skin: A report of three cases.
    Ferrara G; Bradamante M; Broglia I; Petrillo G; Stefanato CM
    J Cutan Pathol; 2020 Jul; 47(7):649-653. PubMed ID: 32109330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
    Alomari AK; Tharp AW; Umphress B; Kowal RP
    J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions.
    Olds H; Utz S; Abrams J; Terrano D; Mehregan D
    J Cutan Pathol; 2022 Jun; 49(6):510-514. PubMed ID: 35146798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRAME immunohistochemistry for melanoma diagnosis: A STARD-compliant diagnostic accuracy study.
    O'Connor MK; Dai H; Fraga GR
    J Cutan Pathol; 2022 Sep; 49(9):780-786. PubMed ID: 35672262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quantitative comparison between SOX10 and MART-1 immunostaining to detect melanocytic hyperplasia in chronically sun-damaged skin.
    Muzumdar S; Argraves M; Kristjansson A; Ferenczi K; Dadras SS
    J Cutan Pathol; 2018 Apr; 45(4):263-268. PubMed ID: 29377259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nests with numerous SOX10 and MiTF-positive cells in lichenoid inflammation: pseudomelanocytic nests or authentic melanocytic proliferation?
    Silva CY; Goldberg LJ; Mahalingam M; Bhawan J; Wolpowitz D
    J Cutan Pathol; 2011 Oct; 38(10):797-800. PubMed ID: 21812802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunohistochemical analysis of pseudomelanocytic nests mimicking melanoma in situ: report of 2 cases.
    Nicholson KM; Gerami P
    Am J Dermatopathol; 2010 Aug; 32(6):633-7. PubMed ID: 20559116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility and comparative immunohistochemical analysis of MITF-1 and SOX10 to distinguish melanoma in situ and actinic keratosis: a clinicopathological and immunohistochemical study of 70 cases.
    Buonaccorsi JN; Prieto VG; Torres-Cabala C; Suster S; Plaza JA
    Am J Dermatopathol; 2014 Feb; 36(2):124-30. PubMed ID: 23782678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The detectability of intraepidermal melanocytes-A narrative review of immunohistochemical studies.
    Kuźbicki Ł; Brożyna AA
    J Cutan Pathol; 2022 Dec; 49(12):1074-1089. PubMed ID: 35851493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of PRAME immunohistochemistry compared with that of c-Kit, c-Myc, or cyclin D1 for the diagnosis of acral melanocytic tumors.
    Jung JM; Lee MY; Won CH; Chang SE; Lee MW; Lee WJ
    Pathol Int; 2023 Jan; 73(1):27-36. PubMed ID: 36468840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
    Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
    Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic test accuracy meta-analysis of PRAME in distinguishing primary cutaneous melanomas from benign melanocytic lesions.
    Kunc M; Żemierowska N; Skowronek F; Biernat W
    Histopathology; 2023 Jul; 83(1):3-14. PubMed ID: 36942814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
    Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
    Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit.
    Kim YJ; Jung CJ; Na H; Lee WJ; Chang SE; Lee MW; Park CS; Lim Y; Won CH
    Diagn Pathol; 2022 Apr; 17(1):41. PubMed ID: 35484605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.